Roberts Jason A, Choi Gordon Y S, Joynt Gavin M, Paul Sanjoy K, Deans Renae, Peake Sandra, Cole Louise, Stephens Dianne, Bellomo Rinaldo, Turnidge John, Wallis Steven C, Roberts Michael S, Roberts Darren M, Lassig-Smith Melissa, Starr Therese, Lipman Jeffrey
Burns Trauma and Critical Care Research Centre, The University of Queensland, Level 3 Ned Hanlon Building, Royal Brisbane and Women's Hospital, Herston, Queensland, 4029, Australia.
Royal Brisbane & Women's Hospital, Queensland, Australia.
BMC Infect Dis. 2016 Mar 1;16:103. doi: 10.1186/s12879-016-1421-6.
Optimal antibiotic dosing is key to maximising patient survival, and minimising the emergence of bacterial resistance. Evidence-based antibiotic dosing guidelines for critically ill patients receiving RRT are currently not available, as RRT techniques and settings vary greatly between ICUs and even individual patients. We aim to develop a robust, evidence-based antibiotic dosing guideline for critically ill patients receiving various forms of RRT. We further aim to observe whether therapeutic antibiotic concentrations are associated with reduced 28-day mortality.
METHODS/DESIGN: We designed a multi-national, observational pharmacokinetic study in critically ill patients requiring RRT. The study antibiotics will be vancomycin, linezolid, piperacillin/tazobactam and meropenem. Pharmacokinetic sampling of each patient's blood, RRT effluent and urine will take place during two separate dosing intervals. In addition, a comprehensive data set, which includes the patients' demographic and clinical parameters, as well as modality, technique and settings of RRT, will be collected. Pharmacokinetic data will be analysed using a population pharmacokinetic approach to identify covariates associated with changes in pharmacokinetic parameters in critically ill patients with AKI who are undergoing RRT for the five commonly prescribed antibiotics.
Using the comprehensive data set collected, the pharmacokinetic profile of the five antibiotics will be constructed, including identification of RRT and other factors indicative of the need for altered antibiotic dosing requirements. This will enable us to develop a dosing guideline for each individual antibiotic that is likely to be relevant to any critically ill patient with acute kidney injury receiving any of the included forms of RRT.
Australian New Zealand Clinical Trial Registry ( ACTRN12613000241730 ) registered 28 February 2013.
优化抗生素给药剂量是提高患者生存率、减少细菌耐药性产生的关键。目前尚无针对接受肾脏替代治疗(RRT)的重症患者的循证抗生素给药指南,因为不同重症监护病房(ICU)甚至不同患者之间,RRT技术和设置差异很大。我们旨在为接受各种形式RRT的重症患者制定一份可靠的循证抗生素给药指南。我们还旨在观察治疗性抗生素浓度是否与28天死亡率降低相关。
方法/设计:我们设计了一项针对需要RRT的重症患者的多国观察性药代动力学研究。研究使用的抗生素将为万古霉素、利奈唑胺、哌拉西林/他唑巴坦和美罗培南。将在两个单独的给药间隔期间对每位患者的血液、RRT流出液和尿液进行药代动力学采样。此外,还将收集包括患者人口统计学和临床参数以及RRT方式、技术和设置的综合数据集。将采用群体药代动力学方法分析药代动力学数据,以确定与接受RRT的急性肾损伤(AKI)重症患者中五种常用抗生素药代动力学参数变化相关的协变量。
利用收集到的综合数据集,将构建这五种抗生素的药代动力学概况,包括确定RRT以及其他表明需要改变抗生素给药需求的因素。这将使我们能够为每种抗生素制定给药指南,该指南可能适用于任何接受任何一种纳入研究的RRT形式的急性肾损伤重症患者。
澳大利亚新西兰临床试验注册中心(ACTRN12613000241730)于2013年2月28日注册。